

LifeStrands Genomics & Ambry Genetics support Singapore's National Precision Medicine Programme

24 April 2023 | News

To provide laboratory testing for clinical implementation pilots in Phase II of the programme



LifeStrands Genomics, a subsidiary of the Pathology Asia group in Singapore, and Ambry Genetics, a subsidiary of US-based REALM IDx, Inc, have joined forces to provide clinical genetic testing services in Singapore. Together, they have been chosen to support the Clinical Implementation Pilots (CIPs) for Phase II of Singapore's National Precision Medicine (NPM) programme through an open tender commissioned by Precision Health Research, Singapore (PRECISE) – the central entity implementing NPM.

LifeStrands signed a strategic agreement with all public sector healthcare institutions in Singapore, and will provide support to three CIPs for patients with familial hypercholesterolemia, familial and hereditary cancers, and primary glomerular diseases.

As part of the agreement, LifeStrands will provide the testing menu from Ambry Genetics and sequence the samples in its accredited laboratory, while Ambry Genetics will provide data interpretation and reporting.

Precision medicine in Singapore aims to understand how genomic, phenotypic, lifestyle and clinical factors contribute to the health of Singaporeans. It also supports the responsible use of health data in clinical applications with the longer-term goal of addressing Singapore's health care challenges in a sustainable and clinically cost-effective way.